Allostimulatory capacity and cytokine production profiles of normal and TCCM-treated BMDCs. (A) MLR examining the ability of normal and TCCM-treated BMDCs to activate allospecific T cells. Results shown are the mean ± SD of 3 experiments. (B) Intracellular cytokine staining showing the percentages of IL-12- and IL-10-expressing CD11c⁺ cells in normal and TCCM-treated BMDCs. Cells from d10 cultures were analyzed. Representative results of 3 experiments are shown. (C) ELISA results demonstrating the secretion of IL-12 by normal maturing BMDCs and TCCM-treated cells during d8 to d10. Supernatants from cell cultures with the addition of TNF-α and IL-1β were collected at 0, 12, 24, 36, and 48 hours after the addition of the cytokines. Concentration of IL-12 in supernatants was quantified by ELISA. Results shown are the mean ± SD of 3 experiments. ^*P < .05; ^**P < .01 (compared with normal controls).